Telomir Pharmaceuticals Reports Preclinical Data on Telomir-Zn Modulating Metal Balance

Telomir Pharmaceuticals, Inc.

Telomir-Zn induced rapid intracellular zinc increase and labile ferrous iron reduction within 30 minutes in preclinical studies.
Coordinated metal redistribution observed without loss of cell confluence or viability, supporting a non-cytotoxic mechanism.
Findings implicate epigenetic modulation, oxidative stress reduction, and mitochondrial stabilization in cancer and aging models.
Company advancing IND-enabling activities with planned IND submission in Q1 2026.
Manuscript submissions initiated for peer-reviewed journals based on completed studies.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.